Journal List > Allergy Asthma Respir Dis > v.3(1) > 1059157

TOOLS
Sim, Choi, and Kim: ERRATUM: Table Correction. Suppressive effects of long-term treatment with inhaled steroids on hypothalamic-pituitary-adrenal axis in asthma
Erratum

Allergy, Asthma & Respiratory Disease 2015; 3(1): 90-91.

Published online: 31 January 2015

DOI: https://doi.org/10.4168/aard.2015.3.1.90

ERRATUM: Table Correction. Suppressive effects of long-term treatment with inhaled steroids on hypothalamic-pituitary-adrenal axis in asthma

Da Woon Sim, Inseon S. Choi, Seung-Hun Kim

Department of Allergy, Chonnam National University Medical School, Gwangju, Korea.

© 2015 The Korean Academy of Pediatric Allergy and Respiratory Disease; The Korean Academy of Asthma, Allergy and Clinical Immunology

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).
Allergy Asthma Respir Dis 2(4):285-292, September 2014 http://dx.doi.org/10.4168/aard.2014.2.4.285
Some parts of Tables 1 and 2 in this paper was described incorrectly.
The correction should be as follows (underline):
Corrected Tables 1 and 2

Figures and Tables

Table 1

The demographics and clinical characteristics of asthma patients treated with inhaled corticosteroid and classified according to the daily doses of inhaled steroids

aard-3-90-i001
Characteristic Low (n = 8) Medium (n = 19) High (n = 102) P-value
Age (yr) 69.6 ± 3.7 61.4 ± 3.3 68.1 ± 1.5 0.182
Female sex 3 (37.5) 8 (42.1) 47 (46.1) 0.589
Duration of ICS use (day) 1,358 ± 230 1,856 ± 354 1,756 ± 127 0.651
Total ICS amount (mg) 278 ± 64 779 ± 158 1,467 ± 113 0.001
Fluticasone/total ICS ratio (%) 73.8 ± 6.8 62.7 ± 7.8 81.7 ± 2.1 0.006
Oral prednisolone (mg) 0 61 ± 49 559 ± 117 0.082
No. of nasal steroid canister 2.5 ± 1.3 12.7 ± 4.1 18.1 ± 2.1 0.080
FEV1 (% predicted) 53.8 ± 9.1 66.0 ± 6.1 50.1 ± 2.5 0.046
Serum total IgE ≥ 100 IU/mL 5 (62.5) 11 (57.9) 52 (51.0) 0.383
Morning cortisol ≤ 3 µg/dL 1 (12.5) 3 (15.8) 18 (17.6) 0.690
Abnormal ACTH response* 1 (12.5) 7 (36.8) 50 (49.0) 0.036
Adrenal insufficiency† 1 (12.5) 8 (42.1) 51 (50.0) 0.052

Values are presented as mean±standard error or number (%).

ICS, inhaled corticosteroid; FEV1, forced expiratory volume in one second; ACTH, adrenocorticotrophic hormone.

*Abnormal ACTH response: serum cortisol<18 µg/dL before and 60 minutes after administration of 250-µg adrenocorticotrophic hormone. †Adrenal insufficiency: abnormal ACTH response or morning cortisol ≤3 µg/dL.

Table 2

The demographics and clinical characteristics of asthma patients used inhaled corticosteroid only and classified according to the response to a 250-µg ACTH stimulation test*

aard-3-90-i002
Characteristic Normal (n = 59) Abnormal (n = 28) P-value
Age (yr) 69.8 ± 1.8 65.6 ± 2.8 0.202
Female sex 29 (49.2) 11 (39.3) 0.388
Duration of ICS use (day) 1,713 ± 154 2,140 ± 259 0.139
Total ICS amount (mg) 1,173 ± 137 1,524 ± 212 0.159
Fluticasone/total ICS ratio (%) 79.1 ± 3.2 82.7 ± 3.1 0.476
No. of nasal steroid canister 12.5 ± 2.4 23.4 ± 4.1 0.016
FEV1 (% predicted) 53.9 ± 3.4 49.7 ± 4.9 0.481
Serum total IgE ≥ 100 IU/mL (%) 30/57 (52.6) 17/28 (60.7) 0.481
Morning cortisol ≤ 3 µg/dL (%) 1 (1.7) 10 (35.7) <0.001

Values are presented as mean±standard error or number (%).

ACTH, adrenocorticotrophic hormone; ICS, inhaled corticosteroid; FEV1, forced expiratory volume in one second.

*Abnormal ACTH stimulation test: serum cortisol<18 µg/dL before and 60 minutes after administration of 250-µg ACTH.

TOOLS
Similar articles